Acadian Asset Management
DSGN icon

Acadian Asset Management’s Design Therapeutics DSGN Stock Holding History

Acadian Asset Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.77M Sell
537,479
-79,002
-13% -$985K 0.01% 673
2026
Q1 		$6.55M Buy
616,481
+3,713
+0.6% +$37.6K 0.01% 632
2025
Q4 		$5.74M Sell
612,768
-4,721
-0.8% -$37K 0.01% 621
2025
Q3 		$4.65M Sell
617,489
-9,859
-2% -$49.4K 0.01% 663
2025
Q2 		$2.11M Sell
627,348
-3,605
-0.6% -$13.5K ﹤0.01% 814
2025
Q1 		$2.43M Buy
630,953
+63,349
+11% +$302K 0.01% 705
2024
Q4 		$3.5M Sell
567,604
-15,556
-3% -$90K 0.01% 618
2024
Q3 		$3.13M Hold
583,160
– – 0.01% 618
2024
Q2 		$1.95M Buy
583,160
+179,614
+45% +$700K 0.01% 770
2024
Q1 		$1.63M Buy
403,546
+222,805
+123% +$595K 0.01% 707
2023
Q4 		$478K Buy
+180,741
New +$414K ﹤0.01% 1035
2023
Q1 		– Sell
-57,957
Closed -$594K – 1791
2022
Q4 		$594K Buy
+57,957
New +$785K ﹤0.01% 987

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management's DSGN Position: Q2 2026 in Review

Acadian Asset Management reduced its Design Therapeutics (DSGN) stake by 13% in Q2 2026, selling an estimated $985K and leaving 537,479 shares worth $7.77M. The position accounts for 0.01% of the portfolio, ranked #673.

Acadian Asset Management first reported a position in DSGN in Q4 2022 and has held it in 12 quarters since. 81 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Acadian Asset Management held 537,479 shares of Design Therapeutics worth $7.77M as of Q2 2026.
  • Acadian Asset Management sold 79,002 Design Therapeutics shares in Q2 2026, an estimated $985K.
  • Design Therapeutics made up 0.01% of Acadian Asset Management's portfolio in Q2 2026, its #673 holding.
  • Acadian Asset Management first reported a position in Design Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • 81 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.